NASH: Flying The Plane While Building It
NASH: Flying The Plane While Building It
$200.00
Investors are showing interest in the development of treatments for NASH (nonalcoholic steatohepatitis), a type of liver disease, as the pipeline for the disease develops in parallel with those R&D efforts. Get a full view of the promising market for NASH in this article from In Vivo.
Publisher: InVivo
- Description
NASH (nonalcoholic steatohepatitis, a form of liver disease), affects nearly 25% of the US population, and development of treatments for NASH is growing, even as scientists continue to uncover more about this chronic disease. Explore the outlook for NASH, and understand the factors that are driving research and development in the field, with a comprehensive overview from In Vivo that also explores the importance of partnerships and collaboration for the development of NASH treatments, as well as an update on late-stage trials for the disease.
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Nucala 
Sign up to the